Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74. Revenue for the quarter hit $7.57 billion compared to the expected $7.15 billion.
A key highlight was the robust performance in the HIV and oncology segments, contributing to an optimistic assessment of the quarter. However, challenges such as declining Veklury sales and increased research and development expenses were noted.
Source: Gilead Sciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. bps = Basis points.
